Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?. (19th September 2019)

• Record Type: Journal Article
• Authors: Tunstall, Brendan J; Lorrai, Irene; McConnell, Sam A; Gazo, Katrina L; Zallar, Lia J; de Guglielmo, Giordano; Hoang, Ivy; Haass-Koffler, Carolina L; Repunte-Canonigo, Vez; Koob, George F; Vendruscolo, Leandro F; Sanna, Pietro Paolo
• Is Part Of: Alcohol and alcoholism. Volume 54:Number 5(2019)
• Page Start: 497
• Page End: 502
• Publication Date: 2019-09-19
• Subjects: Alcoholism -- Periodicals; 616.861005
• DOI: 10.1093/alcalc/agz054
• Languages: English
• ISSNs: 0735-0414

Abstract

Abstract: Aims: The development of novel and more effective medications for alcohol use disorder (AUD) is an important unmet medical need. Drug repositioning or repurposing is an appealing strategy to bring new therapies to the clinic because it greatly reduces the overall costs of drug development and expedites the availability of treatments to those who need them. Probenecid, p-(di-n-propylsulfamyl)-benzoic acid, is a drug used clinically to treat hyperuricemia and gout due to its activity as an inhibitor of the kidneys' organic anion transporter that reclaims uric acid from urine. Probenecid also inhibits pannexin1 channels that are involved in purinergic neurotransmission and inflammation, which have been implicated in alcohol's effects and motivation for alcohol. Therefore, we tested the effects of probenecid on alcohol intake in rodents. Methods: We tested the effects of probenecid on operant oral alcohol self-administration in alcohol-dependent rats during acute withdrawal as well as in nondependent rats and in the drinking-in-the-dark (DID) paradigm of binge-like drinking in mice. Results: Probenecid reduced alcohol intake in both dependent and nondependent rats and in the DID paradigm in mice without affecting water or saccharin intake, indicating that probenecid's effect was selective for alcohol and not the result of a general reduction in reward. Conclusions: These results raise the possibility that pannexin1 is a novel therapeutic target for the treatment of AUD. The clinical use of probenecid has been found to be generally safe, suggesting that it can be a candidate for drug repositioning for the treatment of AUD. Abstract : Probenecid, a drug currently used in the clinic to treat hyperuricemia, reduced alcohol intake in dependent and nondependent rats and binge-like drinking in mice. These results suggest that probenecid can be a candidate for drug repositioning for the treatment of alcohol use disorder (AUD).